KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
Established targeted therapies, such as Janssen’s interleukin (IL)-12/23 inhibitor Stelara, AbbVie’s tumor necrosis factor-alpha (TNF-α) inhibitor Humira, and Novartis’s IL-17A inhibitor…
Renal anemia is a common complication of chronic kidney disease (CKD). The primary goal of treatment of renal anemia is to increase and maintain Hb levels and reduce the risk of complications of…
The treatment journey for multiple sclerosis (MS) patients in the United States continues to evolve; nearly 20 immunomodulatory disease-modifying therapies (DMTs) are now available to treat the…
The human immunodeficiency virus (HIV) therapy market is dynamic and growing. With the launches of many effective antiretroviral therapies (ARTs), such as Gilead’s Biktarvy and ViiV’s Dovato,…
The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021),…
Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of AD…
Clarivate Epidemiology’s coverage of AD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed…